{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02162693",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CBMG-KOA-Ⅱb"
      },
      "Organization": {
        "OrgFullName": "Cellular Biomedicine Group Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis",
      "OfficialTitle": "A PhaseⅡb, Randomized, Double-blinded, Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2017",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "November 2016",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "March 19, 2014",
      "StudyFirstSubmitQCDate": "June 12, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 13, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 14, 2017",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 17, 2017",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Cellular Biomedicine Group Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "RenJi Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "General Hospital of Chinese Armed Police Force",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Current medication treatments for KOA aim to relieve inflammation and pain, but they do little to delay or reverse the disease progression and most medications have obvious side effects. When the conservative treatments are useless to patients and joint deformities and joint disfunction, the patients may require surgery. Although surgery of the joints can relieve the pain temporarily, long-term effect (over 10 years) is hard to achieve.",
      "DetailedDescription": "Human adipose-derived mesenchymal progenitor cells (haMPCs) are obtained through a series of procedures: firstly, the fresh adipose tissue is digested with collagenase, filtered, centrifuged and then discard mature adipose cells to obtain adipose tissue-derived nuclear cells also called stromal vascular fraction cells (SVFs). In the end, haMPCs are prepared after being purified andamplified to P2-P5. When induced by specific factors, haMPCs have a potential for multilineage differentiation towards bone, cartilage and fat tissue both in vivo and in vitro. The haMPCs can secrete a number of soluble mediators to stimulate the proliferation of endogenous progenitor cells, to act as nutrients, to be immunosuppressive, to be anti-inflammatory, to prevent fibrosis and promote angiogenesis. The cytokines secreted by haMPCs play a synergic role in restoring the dynamic balance of synthesis and decompositon of cartilage tissue, and finally to repair the impaired cartilage."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Knee Osteoarthritis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "53",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal progenitor cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Administrated for intra-articular use of Mesenchymal progenitor cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal progenitor cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Sodium Hyaluronate",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Administrated for intra-articular use of Sodium Hyaluronate.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Sodium Hyaluronate"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal progenitor cells",
            "InterventionDescription": "Administrated for intra-articular injection",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal progenitor cells"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Sodium Hyaluronate",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Sodium Hyaluronate"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Recording of Adverse Events and Serious Adverse Events",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nThe subject is between 18-70 years of age, regardless of gender\nThe subject has a Kellgren-Lawrence grading, as determined by American College of Rheumatology (ACR) criteria for osteoarthritis of the knee, below grade 4\nThe subject or the subject's legally acceptable representative must be willing to participate in the trial, to receive cell therapy and to provide signed and dated informed consent forms\n\nExclusion Criteria:\n\nThe subject has an allergic history or is of an allergic constitution\nThe subject has uncontrolled or hard-to-control diseases of heart, liver, kidney or lung\nThe subject has uncontrolled or hard-to-control diseases of cardiovascular or endocrine system\nThe subject has severe infectious diseases or a malignant tumour\nThe subject has coagulation disorders\nThe subject has a BMI of over 30\nThe subject has used traditional Chinese medicine containing anti-inflammatory agents in the 2 weeks preceding the trial\nThe subject has received other intra-articular injections in the 2 months preceding the trial\nThe subject has complications or diseases of: systemic or rheumatoid arthritis, Chondrocalcinosis articular， Hemochromatosis，inflammatory arthropathy，avascular necrosis of femoral head，Paget's disease，hemophilic arthropathy，infectional arthritis，Charcot's disease，villonodular synovitis or synovial chondromatosis\nThe subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases\nThe subject has a history of alcoholism, drug abuse, or mental illness\nThe subject has participated in any other clinical trial in the 3 months prior to this trial\nThe subject is pregnant, lactating or is planning to conceive within the next 6 months\nThe subject has any other unsuitable or adverse condition to be determined by the investigator",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Chunde Bao, MD",
            "OverallOfficialAffiliation": "RenJi Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Zhongwen Zhang, MD",
            "OverallOfficialAffiliation": "General Hospital of Chinese Armed Police Force",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "General Hospital of Chinese Armed Police Force",
            "LocationCity": "Beijing",
            "LocationCountry": "China"
          },
          {
            "LocationFacility": "Shanghai Renji Hospital",
            "LocationCity": "Shanghai",
            "LocationZip": "200127",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "31113476",
            "ReferenceType": "derived",
            "ReferenceCitation": "Lu L, Dai C, Zhang Z, Du H, Li S, Ye P, Fu Q, Zhang L, Wu X, Dong Y, Song Y, Zhao D, Pang Y, Bao C. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther. 2019 May 21;10(1):143. doi: 10.1186/s13287-019-1248-3."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010003",
            "ConditionMeshTerm": "Osteoarthritis"
          },
          {
            "ConditionMeshId": "D000020370",
            "ConditionMeshTerm": "Osteoarthritis, Knee"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001168",
            "ConditionAncestorTerm": "Arthritis"
          },
          {
            "ConditionAncestorId": "D000007592",
            "ConditionAncestorTerm": "Joint Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000012216",
            "ConditionAncestorTerm": "Rheumatic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12078",
            "ConditionBrowseLeafName": "Osteoarthritis",
            "ConditionBrowseLeafAsFound": "Osteoarthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21321",
            "ConditionBrowseLeafName": "Osteoarthritis, Knee",
            "ConditionBrowseLeafAsFound": "Knee Osteoarthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3628",
            "ConditionBrowseLeafName": "Arthritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9773",
            "ConditionBrowseLeafName": "Joint Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000006820",
            "InterventionMeshTerm": "Hyaluronic Acid"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000276",
            "InterventionAncestorTerm": "Adjuvants, Immunologic"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000055675",
            "InterventionAncestorTerm": "Viscosupplements"
          },
          {
            "InterventionAncestorId": "D000020011",
            "InterventionAncestorTerm": "Protective Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M9030",
            "InterventionBrowseLeafName": "Hyaluronic Acid",
            "InterventionBrowseLeafAsFound": "Induction of anesthesia",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M2780",
            "InterventionBrowseLeafName": "Adjuvants, Immunologic",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M27448",
            "InterventionBrowseLeafName": "Viscosupplements",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M21022",
            "InterventionBrowseLeafName": "Protective Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}